ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print May 15, 2007, 10.1183/09031936.00145906
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diel, R.
Right arrow Articles by Zellweger, J-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diel, R.
Right arrow Articles by Zellweger, J-P.
Eur Respir J 2007; 30:321-332
Copyright ©ERS Journals Ltd 2007

Cost-effectiveness of interferon-{gamma} release assay testing for the treatment of latent tuberculosis

R. Diel1, P. Wrighton-Smith2 and J-P. Zellweger3

1 School of Public Health, University of Düsseldorf, Germany, 2 Oxford Immunotec, Oxford, UK, 3 University Medical Policlinic, Lausanne, Switzerland.

CORRESPONDENCE: R. Diel, School of Public Health, c/o Institute for Medical Sociology, Heinrich Heine University, Post box 101007, D-40001 Düsseldorf, Germany. Fax: 49 40427907185. E-mail: Roland.Diel{at}uni-duesseldorf.de

Keywords: Cost-effectiveness, interferon-{gamma} release assay, latent tuberculosis infection, latent tuberculosis infection treatment, tuberculosis

Received: November 7, 2006
Accepted April 19, 2007

The aim of the present study was to assess the cost-effectiveness of the new T-SPOT.TB assay versus the tuberculin skin test (TST) for screening contacts for latent tuberculosis (TB) infection in Switzerland.

Health and economic outcomes of isoniazid treatment of 20- and 40-yr-old close contacts were compared in a Markov model over a 20-yr period following screening with TST only (at three cut-off values) and T-SPOT.TB alone or in combination with the TST.

T-SPOT.TB-based treatment was cost-effective at \#8342;11,621 and \#8342;23,692 per life-year-gained (LYG) in the younger and older age group, respectively. No TST-based programmes were cost-effective, except at a 15-mm cut-off in the younger group only, where the cost-effectiveness (\#8342;26,451·LYG–1) fell just below the willingness-to-pay threshold. Combination of the TST with T-SPOT.TB slightly reduced the total cost compared with the T-SPOT.TB alone by 4.4 and 5.0% in the younger and older groups respectively. The number of contacts treated to avoid one case of TB decreased from 50 (95% confidence interval 32–106) with the TST (10-mm cut-off) to 18 (95%CI 11–43) if T-SPOT.TB was used.

Using T-SPOT.TB alone or in combination with the tuberculin skin test for screening of close contacts before latent tuberculosis infection treatment is highly cost-effective in reducing the disease burden of tuberculosis.




This article has been cited by other articles:


Home page
Vet Rec.Home page
S. G. Rhodes, T. Gruffydd-Jones, D. Gunn-Moore, and K. Jahans
Interferon-{gamma} test for feline tuberculosis
Vet Rec., April 5, 2008; 162(14): 453 - 454.
[Full Text] [PDF]


Home page
ChestHome page
D. Brodie, D. J. Lederer, J. S. Gallardo, S. H. Trivedi, J. N. Burzynski, and N. W. Schluger
Use of an Interferon-{gamma} Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients
Chest, April 1, 2008; 133(4): 869 - 874.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the European Respiratory Society.